Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Nepean, Canada Clinical Trials

A listing of Nepean, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (452) clinical trials

Comparison of Thermometry in Canada for Pediatrics

This study is designed as a multi-center study. This study will involve collecting temperatures on patients using the InstaTemp MD device and the traditional method used in the clinical setting. Reliability and agreement of the InstaTemp MD will be compared to the current Canadian Paediatric Society's definitely recommended methods of ...

Phase N/A

1.33 miles

Learn More »

Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.

This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.

Phase

1.33 miles

Learn More »

A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

This is an open-label Phase 3 study with a 2-week, double-blind, placebo-controlled, randomized drug withdrawal period to evaluate the safety and efficacy of TEV-50717 tablets in patients who have previously completed participation in Study SD-809-C-17, Study TV50717-CNS-30046, or Study TV50717-CNS-30060.

Phase

1.33 miles

Learn More »

Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism

ADHD is the most common pediatric neurobiological condition affecting approximately five percent of the pediatric population (Faraone, Stephen V., Sergeant, J. et al. 2003; Feldman & Belanger 2009). ASD is being increasingly recognized as affecting a substantial amount of the pediatric population, with recent prevalence data showing 1 in 68 ...

Phase

1.33 miles

Learn More »

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

S42909 is an inhibitor of -Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase which also inhibits vascular leukocyte adhesion to endothelial cells, Matrix Metalloproteinase-2 (MMP-2) and Plasminogen Activator Inhibitor-1 (PAI-1) activity. It is proposed for development in the treatment of venous and mixed leg ulcers. This proof of concept study is a ...

Phase

2.31 miles

Learn More »

Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

The primary objective of this study is to evaluate the efficacy of filgotinib and GS-9876 in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

Phase

2.31 miles

Learn More »

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Phase

2.31 miles

Learn More »

The purpose of this study is to evaluate the efficacy of each strength of INCB018424 cream once daily or twice daily in subjects with atopic dermatitis compared with vehicle cream.

Phase

2.32 miles

Learn More »

Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of GBR 830 in adults with moderate to severe atopic dermatitis.

Phase

2.44 miles

Learn More »

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

This is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month open-label extension ...

Phase

2.44 miles

Learn More »